The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     
Free Stock Picks by Top Performers
SocialPicks is a community where stock investors exchange ideas and track performance of financial bloggers.
Top_member_photos
Get free stock picks and email alerts daily
 
Are you a stock guru?

 stephen     Graphic_subscribe   

    Start Tracking stephen  -  Add to Friends  -  Send Message   
    Community Rank: Analyst (114 pts)  |  Member since 10/09/2007
Picks Performance:
N/A

No percentile ranking
has been calculated.

What's this?
All-time Return
-67.93%
(in over 2 years) 		Risk (SD)
Aggressive
0.00% 		Sharpe Ratio
-49.0
Followers
0 		Winning Picks
0 of 2 		Total Views
914

Shared Picks   |   Personal Portfolio   |   Voted Picks   |   Commented On  

View:   Shared Picks (Quick) / (Detailed)   |    Personal Portfolio

Open  |   Closed  

October 09

   stephen   10/09/07  

This pick is about: Boston Scientific Corp (BSX)
Rating:   Positive   $14.6 (10/09/07)
Gain/Loss:   -41.37% in 777 days
0 pt


Bullish on ACAD ...
   stephen   10/09/07  

This pick is about: ACADIA Pharmaceuticals Inc. (ACAD)
Rating:   Positive   $16.25 (10/09/07)
Gain/Loss:   -91.75% in 777 days
6 pts


        The fundamentals for this company are huge going into future with a big bank balance as of June 30, 2007, ACADIA's cash, cash equivalents, and investment securities totaled $153.9 million and a with a great drugs pipeline thats starting to mature. in dealing with parkinson's and schizophrenia there is a possibility of opening up a huge market 1billion+ market that no one has got a grasp of yet and results so far are good.

       Also out today is an upgrade up target from$18 to $28 http://biz.yahoo.com/ap/071009/acadia_pharma_mover.html?.v=1&... and that could be the tip of ice berg. market cap at $600m  which is small for the potential market it could find itself in , in 2-3 years.

            Program                               INDICATION
  • Pimavanserin            - Parkinson’s Disease Psychosis         - phase 3
  • Pimavanserin            - Schizophrenia                                         - phase 2
  • Pimavanserin            - Sleep Maintenance Insomnia              - phase 2
  • ACP-104                     - Schizophrenia                                         - phase 2b
  • AGN XX/YY                 -  Neuropathic Pain                                   - phase 2
  • AC-262271                - Glaucoma                                                 - IND-TRACK
  • ACP-105                    - Endocrinology                                          - IND-TRACK
  • ACP-106                    - Sleep/Neuropsychiatry                           - IND-TRACK
  • Serotonin                   - Sleep/Neuropsychiatry                          - PRECLINICAL
  • PCAPs                        - Schizophrenia                                        - PRECLINICAL
  • Muscarinic                 - Neuropsychiatry/Other                          - PRECLINICAL
  • CB1                             - Obesity                                                    - PRECLINICAL




most recent quarter : http://ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-...




ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.37% 380
2 Gerald Greene 18.14 +70.70% 210
3 stockmarketfunding.com 17.66 +25.67% 55
4 akiralegrand 13.47 +14.32% 61
5 anup2104 12.13 +78.05% 39


POPULAR STOCKS
Symbol Company Name Sentiment
T AT&T Inc
AIG American International Group Inc.
JNJ Johnson & Johnson
FNM Fannie Mae
CSCO Cisco Systems Inc
KO The CocaCola Company

TODAY'S HEADLINES

TODAY'S TOP PICKS

 
Similarity to Me   ?

Compare Your Portfolio With stephen :
Enter stocks you like & get new ideas daily:

Symbols, separated by space (e.g. AAPL GOOG MSFT)



More about stephen

Avg exp holding time:
778.00 days

Age:
20's

Occupation:
student

Location:
Ireland





IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch